<div>
  <ul>
    <li>
      <p>
        Pillar Biosciences has received FDA approval for its oncoReveal CDx pan-cancer solid tumor in vitro diagnostic (IVD). This approval extends the target area of its oncoReveal Dx from EGFR &amp; KRAS therapy selection in non-small cell lung cancer (NSCLC) and colorectal cancer (CRC) to include general solid tumor profiling.
      </p>
    </li>
    <li>
      <p>
        The oncoReveal CDx pan-cancer solid tumor IVD, which has been validated and approved for use on the 
        <a href="https://www.prnewswire.com/news-releases/illumina-and-pillar-biosciences-partner-to-improve-access-to-personalized-cancer-treatment-options-301884595.html">
          Illumina MiSeq Dx System
        </a>
        , is intended for tumor profiling and therapy selection, covering 22 clinically relevant genes. It is claimed to have the capability to handle up to 46 clinical samples in a single MiSeq Dx run and a sample-to-report time of 48 hours.
      </p>
    </li>
    <li>
      <p>
        Pillar Biosciences is a biotechnology company specializing in next-generation sequencing (NGS) diagnostics for oncology. It develops clinically actionable NGS assays that can be integrated into various laboratories to improve the precision and speed of cancer diagnostics. Pillar Biosciences&rsquo; proprietary technologies include the SLIMamp and PiVAT, designed to reduce the complexity and time needed for diagnostic processes. 
      </p>
    </li>
  </ul>
  <p>
  </p>
</div>


<div>
  <p>
    <a href="https://www.prnewswire.com/news-releases/pillar-biosciences-oncoreveal-cdx-pan-cancer-solid-tumor-ivd-now-fda-approved-for-general-tumor-profiling-on-the-illumina-miseq-dx-system-302123760.html">
      Press release
    </a>
  </p>
</div>


Precision Medicine

<div>
 <p>Pillar Biosciences has been granted FDA approval for its oncoReveal CDx pan-cancer solid tumor in vitro diagnostic (IVD). The approval broadens the target zone of its oncoReveal Dx from EGFR &amp; KRAS therapy selection in non-small cell lung cancer (NSCLC) and colorectal cancer (CRC) to cover general solid tumor profiling.</p>
 <p>The validated and approved for use oncoReveal CDx pan-cancer solid tumor IVD operates on the <a href="https://www.prnewswire.com/news-releases/illumina-and-pillar-biosciences-partner-to-improve-access-to-personalized-cancer-treatment-options-301884595.html"> Illumina MiSeq Dx System </a>. It is designed for tumor profiling and therapy selection, involving 22 clinically significant genes. The system can manage up to 46 clinical samples in one MiSeq Dx run and provides results within 48 hours.</p>
 <p>Pillar Biosciences is a biotechnology firm that focuses on next-generation sequencing (NGS) diagnostics for oncology. It produces clinically actionable NGS assays that can be incorporated into many laboratories to enhance the accuracy and speed of cancer diagnostics. Pillar Biosciences has developed proprietary technologies like the SLIMamp and PiVAT that aim to simplify and hasten diagnostic processes.</p>
</div>

Pillar Biosciences receives FDA approval for expanded oncoReveal CDx diagnostics

PROMINENT_CATEGORY

<div>
 <p>SOPHiA GENETICS has entered a partnership with Syndicate Bio, based in Nigeria, to roll out a new tech, MSK-ACCESS in Africa. The technology is bolstered by SOPHiA DDM liquid biopsy testing, initially to be implemented in Nigeria. </p>
 <p>This collaboration aims to offer exhaustive genomic profiling and liquid biopsy in Africa, potentially enabling significant advancements in both cancer treatment and research. Syndicate Bio will employ SOPHiA’s platform to execute profound sequencing of genes associated with cancer using a small blood sample, enabling fast and comprehensive reports generation. The innovative technology is considered as a non-invasive method for patient monitoring and is projected to enhance precision oncology diagnosis and treatment throughout Africa.</p>
 
</div>

SOPHiA GENETICS partners with Syndicate Bio to introduce cancer diagnostics technology across Africa

<div>
 <p>GeneDx has formed a strategic alliance with Komodo Health to share access to their broad dataset of rare diseases, encompassing data from over half a million exomes. The dataset will be integrated into Komodo Health's proprietary Healthcare Map platform through the MapEnhance feature.</p>
 <p>This collaborative venture leverages GeneDx's extensive rare disease data and Komodo Health's holistic interpretation of patient journeys. The main goal is to promote the advancement of precision medicine, offering biopharmaceutical entities access to a wealth of genetic data, which will help them pinpoint new therapeutic targets and hasten clinical trials. </p>
 <p>Komodo Health, a biotech entity, leverages AI to assemble and arrange large volumes of healthcare data gathered from more than a hundred medical sources and over 330 million individual patients. They have devised a “healthcare map,” which aggregates healthcare data throughout a patient’s journey, producing invaluable insights which can be utilized by life sciences companies, drug developers, and insurance providers.</p>
</div>

GeneDx partners with Komodo Health to expand access to one of the largest rare disease datasets globally

<div>
 <p>INmune Bio, a biotechnology company, has finalized a sale and purchase agreement for its 571,592 shares of common stock and the same number of additional shares at USD 9.15 per warrant. The estimated gross proceeds from this offering stand at around USD 4.8 million, before deductions of relevant fees and expenses. The offering, which closed on April 24, 2024, saw a significant chunk (~20%) being purchased by the company's internal stakeholders, including its officers, employees, and directors.</p>

 <p>Funds raised from this sale will be geared toward the completion of INmune Bio's ongoing AD02 Phase II trial for patients struggling with early onset Alzheimer’s disease. The company will also utilize the proceeds toward the Phase I trial for metastatic castration-resistant prostate cancer, using various tech platforms.</p>

 <p>INmune Bio's primary focus lies in the development of treatments that aim to fight disease by targeting the human body's innate immune system. The biotech firm currently has two core product platforms undergoing clinical trials. Firstly, the Dominant-Negative Tumor Necrosis Factor (DN-TNF) product platform designed to treat cancer, early Alzheimer’s disease, and treatment-resistant depression. Secondly, the Natural Killer Cell Priming Platform (INKmune), engineered to prime a cancer patient’s natural killer (NK) cells to eliminate minimal residual disease (MRD). </p>
</div>

INmune Bio raises USD 4.8 million via direct offering to complete ongoing clinical trials

<div>
 <p>Plus Therapeutics has been recommended for a grant of USD 3 million by the Department of Defense's Congressionally Directed Medical Research Programs office. The grant is expected to be disbursed from the third quarter of 2024.</p>
 <p>The grant proceeds will be utilized to expand the clinical trial for the treatment of pediatric brain cancer led by the company. The beginning of this initiative is expected to be in the second half of 2024, post-contract finalization. This funding is also projected to aid the development of Rhenium (186Re) obisbemeda, a new injectable radiotherapy for brain tumors, commencing in the second half of 2025.</p>
 <p>Plus Therapeutics works on the development of targeted radiotherapeutics for the treatment of challenging central nervous system cancers. Its techniques encompass unique image-guided local beta radiation and targeted drug delivery strategies.</p>

</div>

Plus Therapeutics receives USD 3 million grant recommendation from DoD to advance pediatric brain cancer treatment

<div>
 <p>NeuroSense Therapeutics and Genetika+ have entered into a multi-phase collaboration, beginning with NeuroSense's ongoing Phase II clinical trial for Alzheimer's Disease. They will use Genetika+'s technology, which derives frontal cortex neurons from blood samples, to measure drug-induced neuronal plasticity in vitro.</p>
 <p>The technology is expected to aid in the Phase II trials by correlating the clinical response and cellular impact of NeuroSense's therapeutic candidate, PrimeC. This is an extended-release oral formulation combining ciprofloxacin and celecoxib, targeting multiple Alzheimer’s-related pathologies.</p>
 <p>NeuroSense Therapeutics is an Israel-based biopharmaceutical company concentrating on tackling neurodegenerative diseases. Their focus is on developing new therapeutic solutions for conditions like amyotrophic lateral sclerosis (ALS), Parkinson's disease, and Alzheimer's disease.</p>
</div>

NeuroSense Therapeutics collaborates with Genetika+ for Alzheimer's disease drug development

ANALYST_QUICK_TAKE

<div>
 
 <p>SynOx Therapeutics has raised USD 75 million in a Series B funding round, bringing its total funding to approximately USD 119 million. The round was led by Forbion and HealthCap, with new investor Bioqube Ventures also participating.</p>
 <p>The funds will be utilized to generate Phase 3 clinical and CMC data for emactuzumab, a monoclonal antibody developed by SynOx. Emactuzumab targets Tenosynovial Giant Cell Tumour (TGCT) and is potentially a leading CSF-1(R) inhibitor in its class.</p>
 <p>In previous TGCT clinical trials, emactuzumab has shown promising results. It achieved an objective response rate (ORR) of 71% and demonstrated tumor shrinkage, sustained efficacy, and improvements in functional capacity.</p>
 <p>SynOx Therapeutics, a biotech research firm focusing on TGCT therapies, was founded in November 2020. The company acquired exclusive global rights to emactuzumab from Roche under a licensing agreement.</p>
 
</div> <p><b>Analyst QuickTake:<br>
 </b> Prior to this, in August 2022, the European Medicines Agency (EMA) granted orphan medicinal product designation to emactuzumab for treating TGCT, including both localized and diffuse forms of the disease.</p>

SynOx Therapeutics raises USD 75 million in Series B funding to produce Phase 3 clinical and CMC data for emactuzumab

<div>
 <p>Evotec and Variant Bio have partnered to develop treatment options for fibrotic diseases. The partnership leverage Variant Bio's genomic discovery expertise and VB-Inference platform along with Evotec's data on antifibrotic drug discovery and end-to-end R&amp;D platform. The collaboration aims to identify small molecules that target fibrotic pathways and progress them to becoming a clinical development candidate. Additionally, the collaboration enables evaluation of nephrology targets through Evotec's molecular patient database.</p>
 <p>As part of the partnership, Evotec will receive research funding and could potentially receive additional milestone payments and/or royalties, with the specific details undisclosed. The deal also allows Variant Bio to minimize early drug development costs in return for part of potential future profits.</p>
 <p>Variant Bio is a biotech firm that specializes in therapy development by studying human genetics. Their portfolio includes several programs at various stages, focusing on therapeutic areas such as inflammation-immunology, fibrosis, and kidney diseases.</p>
</div>

Evotec and Variant Bio partner to develop treatment for fibrotic diseases

<div>
 <p>ABVC BioPharma's subsidiary, AiBtl BioPharma, has acquired precision medicine manufacturer TT Life Company. The deal involved the purchase of 1.66 million shares at USD 5.00 per share, putting the deal's value at around USD 8.33 million. Other acquisitions included a Malaysian import trading company and a Taiwanese direct sales company.</p>
 <p>Taking advantage of TT Life Company's expertise in product design and manufacturing, the acquisition is expected to create synergies across research &amp; development, manufacturing, distribution, and financial capabilities. This could allow AiBtl to introduce a broad range of AI-driven precision medicines.</p>
 <p>As a biopharmaceutical company, AiBtl BioPharma focuses on the development of innovative therapies for central nervous system disorders such as major depressive disorder (MDD) and ADHD. Their approach involves the use of plant-based norepinephrine transporter inhibitors, currently in clinical trials. One drug is in Phase IIb trials, while another has finished Phase II and is moving towards Phase III. While the company operates from the United States, it has substantial activities in Asia, with clinical trials conducted in Cambodia, Thailand, and Japan.</p>
</div>

AiBtl BioPharma acquires TT Life Company to broaden precision product portfolio

<div>
 <p>Diamyd Medical has recently concluded its company rights issue which ended on April 16, 2024. Several key individuals including the founder and chairman of the board, Bertil Lindkvist, who is also the company’s principal shareholder, as well as other top-ranking executives and board members were among the subscribers in the issue.</p>
 <p>The Rights Issue consists of 9,494,799 units, with 4,216,203 units being subscribed for with unit rights, making up approximately 44% of the complete issue. Subscriptions for 558,779 units have been received without unit rights, which represent roughly 6% of the total units offered. The company has announced that it expects the final proceeds from the Rights Issue to be around SEK 57 million, or approximately USD 5.2 million once costs have been deducted, however it has not yet announced the intended use for these funds.</p>
 <p>As part of their ongoing strategy, Diamyd Medical has stated that they plan to persist in their current line of work, particularly following the recent <a href="https://www.diamyd.com/docs/pressClips.aspx?ClipID=4751158#:~:text=About%20Diamyd%20Medical&amp;text=Diamyd%C2%AE%20is%20an%20antigen,designation%20by%20the%20U.S.%20FDA."> receipt of FDA Fast Track designation for their Diamyd therapy product (rhGAD65/alum) </a> , which is being developed to improve glycemic control in those with Stage 3 type 1 Diabetes who possess the genotype HLA DR3-DQ2.</p>
 <p>Diamyd Medical is a company rooted in Sweden that is known for its specialty in developing precision medicine therapies for autoimmune diabetes, including type 1 Diabetes and Latent Autoimmune Diabetes in Adults (LADA). The companies innovative approach to preserving naturally occurring insulin production through their leading product, Diamyd, which is an antigen-specific immunotherapy, sets it apart within its field.</p>
</div>

All Updates